vs
BALCHEM CORP（BCPC）とBRC Group Holdings, Inc.（RILY）の財務データ比較。上の社名をクリックして会社を切り替えられます
BALCHEM CORPの直近四半期売上が大きい（$263.6M vs $188.3M、BRC Group Holdings, Inc.の約1.4倍）。BRC Group Holdings, Inc.の純利益率が高く（47.9% vs 14.9%、差は33.1%）。BALCHEM CORPの前年同期比売上増加率が高い（9.8% vs -21.9%）。過去8四半期でBALCHEM CORPの売上複合成長率が高い（4.9% vs -15.4%）
バルケムコーポレーションはグローバルな特殊化学品・栄養原料サプライヤーで、人用栄養、動物保健、医薬品、工業用途の4分野を中心に、用途に応じた高品質な製品を北米、欧州、アジア太平洋地域の顧客に提供している。
BCPC vs RILY — 直接比較
売上が大きい
BCPC
1.4倍大きい
$188.3M
売上成長率が高い
BCPC
+31.7%の差
-21.9%
純利益率が高い
RILY
純利益率が33.1%高い
14.9%
2年売上CAGRが高い
BCPC
2年複合成長率
-15.4%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $263.6M | $188.3M |
| 純利益 | $39.2M | $90.3M |
| 粗利率 | 35.6% | 79.5% |
| 営業利益率 | 19.8% | 32.3% |
| 純利益率 | 14.9% | 47.9% |
| 売上前年比 | 9.8% | -21.9% |
| 純利益前年比 | 16.8% | 1710.8% |
| EPS（希薄化後） | $1.21 | $2.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上BCPCRILY
| Q4 25 | $263.6M | $188.3M | ||
| Q3 25 | $267.6M | $215.3M | ||
| Q2 25 | $255.5M | $188.2M | ||
| Q1 25 | $250.5M | $197.2M | ||
| Q4 24 | $240.0M | $241.0M | ||
| Q3 24 | $239.9M | $225.5M | ||
| Q2 24 | $234.1M | $256.0M | ||
| Q1 24 | $239.7M | $263.4M |
純利益BCPCRILY
| Q4 25 | $39.2M | $90.3M | ||
| Q3 25 | $40.3M | $91.1M | ||
| Q2 25 | $38.3M | $139.5M | ||
| Q1 25 | $37.1M | $-10.0M | ||
| Q4 24 | $33.6M | $-5.6M | ||
| Q3 24 | $33.8M | $-284.4M | ||
| Q2 24 | $32.1M | $-433.6M | ||
| Q1 24 | $29.0M | $-49.2M |
粗利率BCPCRILY
| Q4 25 | 35.6% | 79.5% | ||
| Q3 25 | 35.7% | 83.7% | ||
| Q2 25 | 36.4% | 81.3% | ||
| Q1 25 | 35.2% | 81.4% | ||
| Q4 24 | 36.0% | 79.8% | ||
| Q3 24 | 35.6% | 82.1% | ||
| Q2 24 | 35.5% | 84.5% | ||
| Q1 24 | 34.0% | 85.3% |
営業利益率BCPCRILY
| Q4 25 | 19.8% | 32.3% | ||
| Q3 25 | 20.4% | 30.4% | ||
| Q2 25 | 20.1% | 5.7% | ||
| Q1 25 | 20.4% | -31.2% | ||
| Q4 24 | 19.8% | -69.2% | ||
| Q3 24 | 20.0% | -36.4% | ||
| Q2 24 | 19.6% | -90.8% | ||
| Q1 24 | 17.4% | -6.1% |
純利益率BCPCRILY
| Q4 25 | 14.9% | 47.9% | ||
| Q3 25 | 15.1% | 42.3% | ||
| Q2 25 | 15.0% | 74.1% | ||
| Q1 25 | 14.8% | -5.1% | ||
| Q4 24 | 14.0% | -2.3% | ||
| Q3 24 | 14.1% | -126.1% | ||
| Q2 24 | 13.7% | -169.4% | ||
| Q1 24 | 12.1% | -18.7% |
EPS（希薄化後）BCPCRILY
| Q4 25 | $1.21 | $2.78 | ||
| Q3 25 | $1.24 | $2.91 | ||
| Q2 25 | $1.17 | $4.50 | ||
| Q1 25 | $1.13 | $-0.39 | ||
| Q4 24 | $1.03 | $-0.01 | ||
| Q3 24 | $1.03 | $-9.39 | ||
| Q2 24 | $0.98 | $-14.35 | ||
| Q1 24 | $0.89 | $-1.71 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $74.6M | $226.6M |
| 総負債低いほど良い | — | $1.4B |
| 株主資本純資産 | $1.3B | $-171.5M |
| 総資産 | $1.7B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資BCPCRILY
| Q4 25 | $74.6M | $226.6M | ||
| Q3 25 | $65.1M | $184.2M | ||
| Q2 25 | $65.4M | $267.4M | ||
| Q1 25 | $49.9M | $138.3M | ||
| Q4 24 | $49.5M | $146.9M | ||
| Q3 24 | $73.7M | $159.2M | ||
| Q2 24 | $63.7M | $236.9M | ||
| Q1 24 | $60.3M | $190.7M |
総負債BCPCRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
株主資本BCPCRILY
| Q4 25 | $1.3B | $-171.5M | ||
| Q3 25 | $1.3B | $-260.5M | ||
| Q2 25 | $1.3B | $-351.7M | ||
| Q1 25 | $1.2B | $-496.8M | ||
| Q4 24 | $1.1B | $-488.2M | ||
| Q3 24 | $1.2B | $-497.6M | ||
| Q2 24 | $1.1B | $-218.3M | ||
| Q1 24 | $1.1B | $228.4M |
総資産BCPCRILY
| Q4 25 | $1.7B | $1.7B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.6B | $2.2B | ||
| Q2 24 | $1.6B | $3.2B | ||
| Q1 24 | $1.6B | $5.0B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $67.3M | $26.2M |
| フリーキャッシュフロー営業CF - 設備投資 | — | — |
| FCFマージンFCF / 売上 | — | — |
| 設備投資強度設備投資 / 売上 | — | — |
| キャッシュ転換率営業CF / 純利益 | 1.72× | 0.29× |
| 直近12ヶ月FCF直近4四半期 | — | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローBCPCRILY
| Q4 25 | $67.3M | $26.2M | ||
| Q3 25 | $65.6M | $-60.6M | ||
| Q2 25 | $47.3M | $-25.6M | ||
| Q1 25 | $36.5M | $184.0K | ||
| Q4 24 | $52.3M | $-2.7M | ||
| Q3 24 | $51.3M | $19.5M | ||
| Q2 24 | $45.0M | $111.5M | ||
| Q1 24 | $33.4M | $135.4M |
キャッシュ転換率BCPCRILY
| Q4 25 | 1.72× | 0.29× | ||
| Q3 25 | 1.63× | -0.66× | ||
| Q2 25 | 1.23× | -0.18× | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | 1.15× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
